Alcidion GroupASX:ALC 50 9-Day RSI is 64.77 as of Jul. 01, 2026. GuruFocus rates ASX:ALC with a GF Score™ of 50/100 and a GF Value™ of A$0.12 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 700 Healthcare Providers & Services companies, Alcidion Group ranks worse than 81.14% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-01), Alcidion Group's 9-Day RSI is 64.77.
The industry rank for Alcidion Group's 9-Day RSI or its related term are showing as below:
ASX:ALC's 9-Day RSI is ranked worse than 81.14% of 700
companies
in the Healthcare Providers & Services industry
Industry Median: 49.325
vs ASX:ALC: 64.77
Alcidion Group (ASX:ALC) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Alcidion Group 9-Day RSI Related Terms
ASX:ALC vs VEEV, BTSG, TEM: 9-Day RSI Comparison
For the Health Information Services subindustry, Alcidion Group's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcidion Group 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Alcidion Group's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Alcidion Group's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcidion Group (ASX:ALC) has a 9-Day RSI of 64.77 as of Jul. 01, 2026. According to the industry distribution chart, Alcidion Group ranks #568 out of 700 companies in the Healthcare Providers & Services industry, placing it in the top 81.1%.
Is Alcidion Group's 9-Day RSI too high?
Alcidion Group's current 9-Day RSI is 64.77. The Healthcare Providers & Services industry median 9-Day RSI is 49.33. Alcidion Group's value of 64.77 is 31.3% above this industry median. Based on the distribution chart, Alcidion Group ranks #568 out of 700 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Alcidion Group has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcidion Group's 9-Day RSI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Alcidion Group ranks #568 out of 700 companies for 9-Day RSI. This places Alcidion Group in the lower half of its industry. The industry median 9-Day RSI is 49.33. Alcidion Group's value of 64.77 is 31.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 49.33, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcidion Group's current 9-Day RSI of 64.77 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 49.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcidion Group's current 9-Day RSI is 64.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcidion Group stock overvalued right now?
Based on GuruFocus' analysis, Alcidion Group (ASX:ALC) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.12, compared to a current price of A$0.11 — trading 12.5% below its estimated fair value. The current 9-Day RSI is 64.77 and 31.3% above the Healthcare Providers & Services industry median of 49.33. Alcidion Group's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Alcidion Group (ASX:ALC), the current 9-Day RSI is 64.77 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcidion Group (ASX:ALC) Overvalued in 2026?
Based on GuruFocus' analysis, Alcidion Group stock appears to be undervalued.
The current stock price of A$0.11 is trading 12.5% below its estimated GF Value™ of A$0.12.
GuruFocus considers Alcidion Group to be Modestly Undervalued.
Key valuation signals for ASX:ALC:
9-Day RSI: 64.77
GF Value™: A$0.12 vs. price of A$0.11 (12.5% below fair value)
Industry Position: 31.3% above the Healthcare Providers & Services median (#568 of 700)
No single metric tells the full story. See the ASX:ALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcidion Group Ltd is a provider of intelligent informatics software. It offers a fully integrated digital patient care platform that includes a clinical decision support (CDS) system, Electronic Patient Record (EPR), and Patient Administration System (PAS). Alcidion is engaged in the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of healthcare software products from its strategic partners, and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in the United Kingdom, Australia, and New Zealand. The company generates maximum revenue from the United Kingdom.
50GF Score
Get the complete analysis for ASX:ALC
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ALC has been successfully added to your 